drugset / Trial / NCT06956196
Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.
Timeline
- Start
- 2025-05
- Primary completion
- 2026-05
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Stapokibatrt | Unknown | 1 ml | Subcutaneous |
| Subject | Stapokibatrt | Unknown | 2 ml | Subcutaneous |